Search Within

Matthew David Hellmann

  1. "2017"
Formats
  1. Journal Article (22)
  2. Meeting Abstract (22)
Groups
  1. Department of Medicine (44)
  2. Solid Tumor Oncology Division (44)
  3. Thoracic Oncology (44)
  4. Melanoma and Immunotherapeutics Service (13)
  5. GSK Faculty (12)
  6. Department of Pathology and Laboratory Medicine (10)

More Groups

People
  1. Jamie Chaft (7)
  2. Jedd Wolchok (7)
  3. Margaret Callahan (6)
  4. Natasha Rekhtman (6)
  5. Alexandra Snyder Charen (5)
  6. Hira Rizvi (5)

More People

Years
  1. 2017 (44)
Publications
  1. Journal of Clinical Oncology (9)
  2. Annals of Oncology (6)
  3. Journal of Thoracic Oncology (3)
  4. Asia-Pacific Journal of Clinical Oncology (2)
  5. Cancer Immunology Research (2)
  6. Journal for ImmunoTherapy of Cancer (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (10)
  2. Oxford University Press (8)
  3. Nature Publishing Group (5)
  4. Elsevier Inc. (4)
  5. American Association for Cancer Research (3)
  6. Biomed Central Ltd (2)

More Publishers

Results (44)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab alone or with ipilimumab in recurrent small cell lung cancer (SCLC): 2-year survival and apdated analyses from the CheckMate 032 trial
    Meeting Abstract

    Hellmann, M.; Antonia, S.; Ponce, S.; Ott, P.; Calvo, E.; Taylor, M.; Ready, N.; Hann, C.; De Braud, F.; Eder, J. P.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Tumor mutation burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L+ NSCLC patients
    Meeting Abstract

    Kowanetz, M.; Zou, W.; Shames, D.; Cummings, C.; Rizvi, N.; Spira, A.; Frampton, G.; Leveque, V.; Flynn, S.; Mocci, S.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • First-line nivolumab monotherapy and nivolumab plus ipilimumab in patients with advanced NSCLC: Long-term outcomes from CheckMate 012
    Meeting Abstract

    Gettinger, S.; Rizvi, N.; Chow, L.; Borghaei, H.; Brahmer, J.; Shepherd, F.; Ready, N.; Gerber, D.; Antonia, S.; Goldman, J. W.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
    Journal Article

    Luksza, M.; Riaz, N.; Makarov, V.; Balachandran, V. P.; Hellmann, M. D.; Solovyov, A.; Rizvi, N. A.; Merghoub, T.; Levine, A. J.; Chan, T. A.; more...
    Nature (2017)

    Fulltext@MSK | Save
  • Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)
    Journal Article

    Horn, L.; Spigel, D. R.; Vokes, E. E.; Holgado, E.; Ready, N.; Steins, M.; Poddubskaya, E.; Borghaei, H.; Felip, E.; Paz-Ares, L.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer
    Journal Article

    Topper, M. J.; Vaz, M.; Chiappinelli, K. B.; DeStefano Shields, C. E.; Niknafs, N.; Yen, R. W. C.; Wenzel, A.; Hicks, J.; Ballew, M.; Stone, M.; more...
    Cell (2017)

    Fulltext@MSK | Save
  • Lesion response and intracranial control of brain metastases from non-small cell lung cancer after stereotactic radiosurgery or hypofractionated radiation therapy combined with checkpoint inhibitors
    Meeting Abstract

    Imber, B. S.; Hellmann, M. D.; Kris, M. G.; Santomasso, B. D.; Callahan, M. K.; Osorio, J.; Rizvi, H.; Chan, T. A.; Yang, T. J.; Yamada, Y.; more...
    International Journal of Radiation Oncology, Biology, Physics (2017)

    Fulltext@MSK | Save
  • Lung cancer patient selection (clinical biomarkers)
    Meeting Abstract

    Hellmann, M. D.
    Asia-Pacific Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab
    Meeting Abstract

    Hellmann, M. D.; Leighl, N. B.; Hui, R.; Carcereny, E.; Felip, E.; Ahn, M. J.; Eder, J. P.; Balmanoukian, A. S.; Aggarwal, C.; Horn, L.; more...
    Asia-Pacific Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Evaluation of nivolumab (nivo) alone and in combination with ipilimumab (ipi) in patients (pts) with advanced (adv) small-cell lung cancer (SCLC): First report of a randomized expansion cohort from the CheckMate 032 trial
    Meeting Abstract

    Atmaca, A.; Hellmann, M. D.; Ott, P. A.; Zugazagoitia, J.; Ready, N.; Hann, C. L.; De Braud, F.; Antonia, S.; Ascierto, P.; Moreno, V.; more...
    Oncology Research and Treatment (2017)

    Fulltext@MSK | Save